NTLA Insider Trading
Intellia Therapeutics, Inc. | In Vitro & In Vivo Diagnostic Substances
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Intellia Therapeutics, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the In Vitro & In Vivo Diagnostic Substances sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-08 00:05 | 2026-01-05 | LEONARD JOHN M | Director, Officer - President and CEO | SELL | $9.21 | 34,146 | $314,485 | 1,013,339 | -3.3% |
| 2026-01-08 00:05 | 2026-01-05 | Schultes Birgit C | Officer - EVP, Chief Scientific Officer | SELL | $9.21 | 8,508 | $78,359 | 98,533 | -7.9% |
| 2026-01-08 00:05 | 2026-01-05 | BASTA JAMES | Officer - EVP, General Counsel | SELL | $9.21 | 10,397 | $95,756 | 101,528 | -9.3% |
| 2026-01-08 00:05 | 2026-01-05 | Cohen Fred E | Director | BUY | $9.35 | 150,000 | $1,402,500 | 207,453 | +261.1% |
| 2026-01-08 00:04 | 2026-01-05 | Lebwohl David | Officer - EVP, Chief Medical Officer | SELL | $9.21 | 11,903 | $109,627 | 121,249 | -8.9% |
| 2026-01-08 00:03 | 2026-01-05 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $9.21 | 9,515 | $87,633 | 87,118 | -9.8% |
| 2026-01-08 00:02 | 2026-01-05 | Dulac Edward J III | Officer - EVP, Chief Financial Officer | SELL | $9.21 | 6,379 | $58,751 | 99,683 | -6.0% |
| 2026-01-08 00:01 | 2026-01-05 | Dube Michael P | Officer - VP, Chief Accounting Officer | SELL | $9.21 | 2,989 | $27,529 | 52,277 | -5.4% |
| 2025-12-13 00:09 | 2025-12-11 | LEONARD JOHN M | Director, Officer - President and CEO | OPT+S | $9.49 | 88,146 | $836,382 | 1,038,928 | 0.0% |
| 2025-10-04 00:13 | 2025-10-01 | Schultes Birgit C | Officer - EVP, Chief Scientific Officer | SELL | $17.38 | 31 | $539 | 105,184 | 0.0% |
| 2025-10-04 00:13 | 2025-10-01 | Dube Michael P | Officer - VP, Chief Accounting Officer | SELL | $17.38 | 1,871 | $32,518 | 55,266 | -3.3% |
| 2025-08-22 23:30 | 2025-08-20 | CHASE WILLIAM J | Director | BUY | $10.03 | 100,000 | $1,003,000 | 134,693 | +288.2% |
| 2025-07-25 23:05 | 2025-07-23 | Dulac Edward J III | Officer - EVP, Chief Financial Officer | SELL | $14.02 | 7,462 | $104,617 | 106,062 | -6.6% |
| 2025-07-03 23:11 | 2025-07-01 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $9.82 | 1,022 | $10,036 | 95,369 | -1.1% |
| 2025-07-03 23:07 | 2025-07-02 | Dube Michael P | Officer - VP, Chief Accounting Officer | SELL | $9.95 | 2,503 | $24,905 | 57,137 | -4.2% |
| 2025-07-03 00:50 | 2025-06-30 | GOODMAN JESSE | Director | SELL | $9.40 | 3,094 | $29,068 | 24,359 | -11.3% |
| 2025-05-01 23:24 | 2025-04-29 | Bhanji Muna | Director | SELL | $8.50 | 265 | $2,253 | 19,203 | -1.4% |
| 2025-03-05 00:43 | 2025-03-04 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $8.99 | 679 | $6,104 | 95,369 | -0.7% |
| 2025-03-05 00:21 | 2025-03-04 | BASTA JAMES | Officer - EVP, General Counsel | SELL | $8.99 | 2,572 | $23,122 | 111,925 | -2.2% |
| 2025-02-01 00:17 | 2025-01-29 | Bhanji Muna | Director | SELL | $9.97 | 265 | $2,642 | 19,468 | -1.3% |
| 2025-01-08 01:23 | 2025-01-03 | Dube Michael P | Officer - VP, Chief Accounting Officer | SELL | $12.18 | 1,372 | $16,711 | 45,640 | -2.9% |
| 2025-01-08 01:22 | 2025-01-03 | BASTA JAMES | Officer - EVP, General Counsel | SELL | $12.18 | 7,074 | $86,161 | 74,497 | -8.7% |
| 2025-01-08 01:20 | 2025-01-03 | Lebwohl David | Officer - EVP, Chief Medical Officer | SELL | $12.18 | 9,557 | $116,404 | 87,666 | -9.8% |
| 2025-01-08 01:20 | 2025-01-03 | Hicks Derek | Officer - EVP, Chief Business Officer | SELL | $12.18 | 6,502 | $79,194 | 59,878 | -9.8% |
| 2025-01-08 01:19 | 2025-01-03 | LEONARD JOHN M | Director, Officer - President and CEO | SELL | $12.18 | 26,807 | $326,509 | 941,115 | -2.8% |
| 2025-01-08 01:16 | 2025-01-03 | Sepp-Lorenzino Laura | Officer - EVP, Chief Scientific Officer | SELL | $12.18 | 8,966 | $109,206 | 77,388 | -10.4% |
| 2025-01-07 00:16 | 2025-01-02 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $12.17 | 7,978 | $97,088 | 64,048 | -11.1% |
| 2024-10-05 00:29 | 2024-10-02 | Dube Michael P | Officer - VP, Chief Accounting Officer | SELL | $19.01 | 2,012 | $38,248 | 47,012 | -4.1% |
| 2024-07-03 20:15 | 2024-07-01 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $22.93 | 405 | $9,287 | 71,470 | -0.6% |
| 2024-06-21 00:00 | 2024-06-17 | Verwiel Frank | Director | SELL | $25.00 | 1,505 | $37,625 | 17,948 | -7.7% |
| 2024-03-06 00:10 | 2024-03-04 | BASTA JAMES | Officer - EVP, General Counsel | SELL | $32.99 | 2,297 | $75,778 | 81,571 | -2.7% |
| 2024-03-06 00:10 | 2024-03-04 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $32.99 | 605 | $19,959 | 71,470 | -0.8% |
| 2024-01-11 00:15 | 2024-01-08 | Sepp-Lorenzino Laura | Officer - EVP, Chief Scientific Officer | SELL | $28.87 | 2,275 | $65,682 | 43,927 | -4.9% |
| 2024-01-06 00:51 | 2024-01-03 | LEONARD JOHN M | Director, Officer - President and CEO | SELL | $29.46 | 19,223 | $566,310 | 846,486 | -2.2% |
| 2024-01-06 00:50 | 2024-01-03 | Lebwohl David | Officer - EVP, Chief Medical Officer | SELL | $29.46 | 5,843 | $172,135 | 54,372 | -9.7% |
| 2024-01-06 00:50 | 2024-01-03 | Sepp-Lorenzino Laura | Officer - EVP, Chief Scientific Officer | SELL | $29.46 | 5,532 | $162,973 | 46,202 | -10.7% |
| 2024-01-06 00:49 | 2024-01-03 | Goddard Glenn | Officer - EVP, Chief Financial Officer | SELL | $29.46 | 5,365 | $158,053 | 40,585 | -11.7% |
| 2024-01-06 00:46 | 2024-01-03 | Hicks Derek | Officer - EVP, Chief Business Officer | SELL | $29.46 | 3,877 | $114,216 | 36,987 | -9.5% |
| 2024-01-06 00:45 | 2024-01-03 | BASTA JAMES | Officer - EVP, General Counsel | SELL | $29.46 | 3,805 | $112,095 | 51,474 | -6.9% |
| 2024-01-06 00:44 | 2024-01-03 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $29.50 | 4,608 | $135,954 | 40,845 | -10.1% |
| 2023-11-02 23:42 | 2023-10-31 | Bhanji Muna | Director | SELL | $23.90 | 265 | $6,334 | 11,996 | -2.2% |
| 2023-08-03 00:19 | 2023-07-31 | Bhanji Muna | Director | SELL | $42.33 | 265 | $11,217 | 12,261 | -2.1% |
| 2023-07-11 00:21 | 2023-07-06 | Bhanji Muna | Director | SELL | $39.30 | 1,867 | $73,373 | 12,526 | -13.0% |
| 2023-07-06 22:34 | 2023-07-03 | Clark Eliana | Officer - EVP, Chief Technical Officer | SELL | $40.51 | 360 | $14,584 | 45,146 | -0.8% |
| 2023-06-23 00:52 | 2023-06-20 | Clark Eliana | Officer - EVP, Chief Technical Officer | OPT+S | $45.00 | 5,000 | $225,000 | 45,146 | 0.0% |
| 2023-03-04 01:10 | 2023-03-02 | BASTA JAMES | Officer - EVP, General Counsel | SELL | $43.88 | 1,088 | $47,741 | 55,279 | -1.9% |
| 2023-01-07 01:39 | 2023-01-04 | Sepp-Lorenzino Laura | Officer - EVP, Chief Scientific Officer | SELL | $37.82 | 4,838 | $182,981 | 17,629 | -21.5% |
| 2023-01-07 01:32 | 2023-01-04 | LEONARD JOHN M | Director, Officer - President and CEO | SELL | $37.21 | 6,673 | $248,302 | 766,825 | -0.9% |
| 2023-01-07 01:29 | 2023-01-04 | Hicks Derek | Officer - EVP, Chief Business Officer | SELL | $37.21 | 1,812 | $67,425 | 17,306 | -9.5% |
| 2023-01-07 01:26 | 2023-01-04 | Lebwohl David | Officer - EVP, Chief Medical Officer | SELL | $37.21 | 2,574 | $95,779 | 25,687 | -9.1% |
How to Interpret $NTLA Trades
Not every insider transaction in Intellia Therapeutics, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $NTLA shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for NTLA
Insider activity data for Intellia Therapeutics, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $NTLA, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.